Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Altia Plc’s Business Review January–March 2018: Start of the year in line with expectations, comparable EBITDA improving

Altia Plc’s Business Review January–March 2018: Start of the year in line with expectations, comparable EBITDA improving January–March 2018 compared to January–March 2017 · Growth in constant currencies was 2.0%, reported net sales of EUR 73.5 (73.4) million were impacted by unfavourable currency fluctuations · The timing of Easter in the first quarter contributed positively to net sales and profitability · Comparable EBITDA was EUR 5.2 (4.3) million, which is 7.0% (5.8%) of net sales · Items affecting comparability were EUR -4.1 (-0.5) million, driven by IPO costs · Net

Arjo interim report January-March 2018

“The strong start to the year with an organic sales growth of 2.3% shows that our increased external focus and the initiatives implemented to date are generating results. We have now taken the first important steps as an independent company and it is gratifying that, for the first time in three years, we are reporting a positive organic sales growth. The strong beginning of the year means that we now, with even more confidence, believe that we will reach our 2018 target of entering the lower end of 2-4% sales growth”, says Joacim Lindoff, President & CEO. January-March 2018 in brief

Asetek Receives Follow-on Order From Penguin Computing

Aalborg, Denmark, 4 May 2018 – Asetek today announced a further order from Penguin Computing, an established data center OEM, for further build-out of an undisclosed U.S. Department of Energy High Performance Computing (HPC) installation. Today’s follow-on order includes Asetek’s RackCDU™ Direct-to-Chip (D2C) liquid cooling solution and D2C coolers and loops for OCP-based Tundra™ Relion™ nodes using both NVIDIA®’s P100 GPU accelerators and Intel® Xeon® ES-2600 processors. The order has a value of USD 230,000 with delivery to be completed in Q3 2018. About AsetekAsetek is the

Attendo's first quarter report 2018: High pace of openings and strong growth

During the first quarter 2018, Attendo continued to open new nursing homes in own operations at a high pace. By the end of the quarter, Attendo had more than 13 800 own beds in operation – almost 50 % more than one year ago. The high pace of openings contributed to a lower result compared to the first quarter 2017.CEO Pertti Karjalainen comments on the report “In line with our strategy, Attendo is in a period of numerous openings of new homes and a large number of beds under construction. We are building a solid foundation for future growth and long-term value creation. Attendo now has

Ilkka Salonen to join Metsäliitto Cooperative’s Board of Directors

At a meeting held on 3 May 2018, the Supervisory Board of Metsä Group’s parent company, Metsäliitto Cooperative, elected Ilkka Salonen, Master of Science (Econ), to be a new member of Metsäliitto Cooperative’s Board of Directors. Salonen, who works as CFO and Deputy to President and CEO in YIT Corporation, is also the chairman of the Board’s audit committee. Mikael Silvennoinen leaves the Board of Directors. He was a member of the Board since 2015. METSÄ GROUP

InDex Pharmaceuticals develops oral formulation of cobitolimod

May 4, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that it has developed a novel formulation of its lead drug candidate cobitolimod for oral administration, with targeted delivery to the lower part of the gastrointestinal tract. The oral formulation of cobitolimod is a potential follow-on product to the topical formulation, which is currently being investigated in the CONDUCT study - a phase IIb dose optimisation study in moderate to severe active ulcerative colitis.Topical application of cobitolimod can provide rapid onset of action, while minimizing the risk of systemic

BONESUPPORT HOLDING AB (Publ) – Q1 Interim Report

January – March 2018Lund, Sweden, 08.00 CET, 4 May 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces the publication of its Q1 Interim Report - January – March 2018.   BEST QUARTER EVER IN EUROPE FINANCIAL HIGHLIGHTS JANUARY – MARCH 2018 ·  Net Sales amounted to SEK 31.1million (32.5), a decrease of 4%. Sales were flat in constant currency terms and were 15.2% higher than Q4 2017 ·  Gross

Invitation to the presentation of Polygon first quarter 2018 report

On Wednesday May 9 2018, at 08:00 CET, Polygon AB (publ) will publish its first quarter 2018 report.Financial analysts and investors in Polygon senior secured notes are invited to participate in a telephone conference on the same day at 13:00 CET where the Q1 report will be presented. The event will be hosted by Polygon´s CEO Erik-Jan Jansen and CFO Mats Norberg. The presentation will be held in English. Slides for the presentation will be made available on our website https://www.polygongroup.com/investors/financial-reports/ prior to the start of the conference. To participate in the

Tikkurila Oyj: Managers' transactions - Jari Paasikivi

Tikkurila OyjManagers' transactionsMay 4, 2018 at 9:00 a.m. (CET+1) Managers' transactions - Jari Paasikivi ____________________________________________ Person subject to the notification requirementName: Paasikivi, JariPosition: Member of the Board/Deputy memberIssuer: Tikkurila OyjLEI: 743700PKLY067IZIF588 Notification type: INITIAL NOTIFICATIONReference number: 743700PKLY067IZIF588_20180503100805_3____________________________________________ Transaction date: 2018-05-02Venue: OFF-EXCHANGE TRANSACTIONS (XOFF)Instrument type: SHAREISIN: FI4000008719

Raisio plc: Changes in Raisio's management

Raisio plc, Stock Exchange Release, 4 May 2018 at 9.00 a.m. Finnish time CHANGES IN RAISIO’S MANAGEMENT Perttu Eerola’s duties as VP of the Raisioagro Division, a Group Management Team member and Raisioagro Ltd’s Managing Director will end on 4 May 2018. Earlier today, Raisio announced to divest Raisioagro’s cattle feed business to Lantmännen Agro Oy. The transaction is expected to take place during September 2018. RAISIO PLC Heidi HirvonenCommunications and IR Managertel. +358 50 567 3060 Further information:Pekka Kuusniemi, President and CEO, tel. +358 50 537 3883

Orkla ASA: Trade subject to notification - treasury shares

Orkla ASA has on 3 May bought 550,000 Orkla shares through broker at an average price of NOK 73.75 per share. Orkla's total holding of treasury shares after this transaction is 1,826,933 shares. Orkla ASAOslo, 4 May 2018Ref.:IR & Communications ManagerElise HeidenreichTel.: +47 951 41 147 This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

INTERIM REPORT JANUARY–MARCH 2018

“The earnings reported in the first quarter of 2018 show that we must take measures to return to growth” Karl Thedéen, CEO EdgewareFIRST QUARTER OF 2018:   · Net sales of SEK 48.4 million (68.7), down 29.5 percent. · Gross profit of SEK 32.3 million (52.4), corresponding to a gross margin of 66.7 percent (76.2). · EBIT of SEK -11.5 million (pos: 13.0), corresponding to an EBIT margin of -23.7 percent (pos: 18.9). · Loss for the period amounted to SEK -9.2 million (profit: 10.3). · Cash flow from operating activities of SEK 6.8 million (4.7). · Earnings per share for the

Apollo Hospitals Group chooses Elekta’s MOSAIQ for new proton center

NEW DELHI, May 4, 2018 – Elekta (EKTA-B.ST) announced today that Asia’s foremost integrated healthcare services provider, Apollo Hospitals, has chosen Elekta's vendor-neutral, open source MOSAIQ®  oncology information system for its Apollo Proton Cancer Centre (APCC) in Chennai, India. The proton therapy solution is being provided by IBA (Ion Beam Applications). Apollo Hospitals expects that this first proton therapy center in South Asia will provide access to this technology to more than three billion people. Ranjit Pradhan, Senior Vice President

Raisio plc's Interim Report January - March 2018

Raisio plc, Interim Report, 4 May 2018 at 8.30 Finnish time RAISIO’S INTERIM REPORT JANUARY-MARCH 2018 January-March 2018, continuing operations · Raisio Group’s net sales totalled EUR 67.8 (69.3) million. · The Group’s comparable EBIT was EUR 7.4 (7.8) million, accounting for 10.9 (11.3)% of net sales. · The Healthy Food Division’s net sales amounted to EUR 48.1 (50.3) million, and comparable EBIT was EUR 8.3 (9.8) million, accounting for 17.2 (19.5)% of net sales. · Net sales for the Raisioagro Division were EUR 19.7 (19.1) million and comparable EBIT was EUR 0.1 (0.3)

Lantmännen acquires cattle feed business from the Finnish company Raisio

Lantmännen is acquiring the cattle feed business from the Finnish listed company Raisio Group. The acquisition is part of Lantmännen's growth strategy in the Baltic Sea region and strengthens Lantmännen's presence on the Finnish market by expanding our offer to farmers there.Lantmännen is acquiring Raisio's cattle feed business including two feed factories and sales of inputs for plant cultivation. Raisio's cattle feed business is a big player on the Finnish agricultural market, with a 35 percent market share of the Finnish cattle feed market and had sales (in 2017) of Euro 74 million.

Read original

Interim report 1 January – 31 March 2018

Important clarifying information IFRS · Oriflame has implemented IFRS 15 Revenue from Contracts with Customers from 1st January 2018. An early adoption of IFRS 16 Leases has been made to allow for all changes being implemented at the same time. · The application of IFRS 15 is impacting the income statement at different levels, both as a one-off adjustment and as reclassifications of costs. In order to facilitate the analysis of the company’s underlying performance and minimize the impact from the one-off adjustment, Oriflame has decided to recognise the new IFRS 15 standard in

NPRO: 1Q 2018 - EARNINGS PER SHARE NOK 0.17, DIVIDEND NOK 0.07 PER SHARE

Pre-tax profit came to NOK 141.7 million (NOK 287.2 million). After NOK 49.4 million in estimated tax expense, net profit for the period came to NOK 92.3 million. That yielded ordinary earnings per share (EPS) of NOK 0.17 for the first quarter. Carried equity per share came to NOK 14.06 at 31 March 2018, up from NOK 13.96 at 31 December 2017 (Epra NAV: NOK 15.47 and Epra NNNAV: NOK 14.65 at 31 March 2018). Link to webcast in Norwegian: http://webtv.hegnar.no/presentation.php?webcastId=83479980  The board of directors has approved a dividend of NOK 0.07 per share to be distributed to

EVRY ASA: Continue the journey with organic revenue growth

(Fornebu, 4 May 2018) EVRY reports total revenue of NOK 3,208 million for the first quarter of 2018, an improvement from NOK 3,177 million in the first quarter of 2017. After adjusting for exchange rate effects and acquisitions, this represents organic growth of 0.5% in the first quarter of 2018. The company delivered EBITA of NOK 320 million in the first quarter of 2018 as compared to NOK 345 million in the first quarter of 2017. “We are pleased to announce that, despite a very strong first quarter in 2017, EVRY continued its journey of achieving organic revenue growth in the first

Pihlajalinna Interim Report 1 January–31 March 2018 (3 months)

Pihlajalinna Plc           Interim Report             4 May 2018 Pihlajalinna Interim Report 1 January–31 March 2018 (3 months) Pihlajalinna’s result weighed down by expansion and structural reforms, outlook unchanged Brief look at January–March: · Revenue amounted to EUR 119.2 (110.0) million – an increase of 8 per cent · EBITDA amounted to EUR 4.3 (8.9) million · Adjusted EBITDA was EUR 3.9 (9.1) million · Operating profit (EBIT) was EUR 0.1 (5.4) million · Adjusted operating result (EBIT) was EUR -0.3 (5.7) million. · The number of personnel at the end of the

NPRO: KEY INFORMATION RELATING TO THE CASH DIVIDEND TO BE PAID BY NORWEGIAN PROPERTY ASA

Dividend amount: NOK 0.07 per share Last day including right: 4 May 2018 Ex date:   7 May 2018 Record date:  8 May 2018 Payment date: 23 May 2018 For additional information, please contact: Bent Oustad, CEOTelephone: +47 48 01 60 82Email: bo@npro.no This information is subject of the disclosure requirements according to §5-12 of the Norwegian Securities Trading Act (’Verdipapirhandelloven’).

TF Bank plans to issue a primary capital instrument (AT1)

TF Bank AB plans to issue a primary capital instrument (AT1) with a nominal amount of 100 million Swedish Krona to facilitate the banks future expansion with optimal capital structure.The new instrument is expected to be issued under the second quarter of 2018 if market conditions are deemed favorable. The instrument shall be listed for trading at Nasdaq Stockholm. Information about the instrument’s terms and conditions publicized at the time of the issuing. For more information you may contact:Mikael Meomuttel, CFO and Head of Investor Relations +46 (0)70 626 95 33 About TF Bank

Raisio plc: Raisio to divest its cattle feed business to Lantmännen

Raisio plc, Stock Exchange Release, 4 May 2018, at 8.00 a.m. Finnish time RAISIO TO DIVEST ITS CATTLE FEED BUSINESS TO LANTMÄNNEN Raisio has signed an agreement to sell its cattle feed business to Lantmännen Agro Oy. The enterprise value is EUR 34 million and the arrangement will be conducted as a share transaction. Raisio’s cattle feed business is expected to transfer to the new owner during September 2018. The completion of the deal requires an approval from the Finnish competition authorities. The fish feed business will continue as a solid part of the Raisio Group. “The cattle

BEWi announces that all regulatory approvals for the acquisition of Synbra have been obtained

Press release 2018-05-03, at 8.30 p.m. CETOn 22 March 2018, BEWi Group AB (publ) (“BEWi”), announced that it, through a Dutch wholly-owned subsidiary, had entered into a share purchase agreement to acquire all the shares in Synbra Holding B.V. (“Synbra”) with certain funds managed by Gilde Buy Out Partners (“Gilde”) and its co-investors as sellers. Completion of the acquisition is subject to financing and regulatory approval. On 12 April 2018, BEWi announced that it successfully placed a senior secured bond loan in an amount of EUR 75 million under a framework of EUR 100 million due in

There are no items matching the current filter
There are no more items matching the current filter
Back to top